<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338621</url>
  </required_header>
  <id_info>
    <org_study_id>SimpliciTB (B-Pa-M-Z) NC-008</org_study_id>
    <nct_id>NCT03338621</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients</brief_title>
  <official_title>An Open-Label, Partially Randomized Trial to Evaluate the Efficacy, Safety and Tolerability of a 4-month Treatment of Bedaquiline Plus Pretomanid Plus Moxifloxacin Plus Pyrazinamide (BPaMZ) Compared to a 6-month Treatment of HRZE/HR (Control) in Adult Participants With Drug-Sensitive Smear-Positive Pulmonary Tuberculosis (DS-TB) and a 6-month Treatment of BPaMZ in Adult Participants With Drug Resistant, Smear-Positive Pulmonary Tuberculosis (DR-TB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Global Alliance for TB Drug Development</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Global Alliance for TB Drug Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy, safety and tolerability at 8 weeks (2-months), 52 weeks&#xD;
      (12-months), and 104 Weeks (24-months) post the start of the following treatment regimens in&#xD;
      participants with: Drug Sensitive TB (DS-TB) patients given BPaMZ for 17 Weeks ( or 4 months)&#xD;
      vs. Standard HRZE/HR treatment given for 26 weeks (or 6 months) and Drug Resistant TB (DR-TB)&#xD;
      patients given BPaMZ for 26 Weeks (or 6 months)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2c multi-center, open-label, partially randomized clinical trial in DS-TB and DR-TB&#xD;
      participants.&#xD;
&#xD;
      All participants in the below arms will have follow-up for a period of 104 weeks (24 months)&#xD;
      from the start of therapy.&#xD;
&#xD;
      Participants with Drug Sensitive TB (DS-TB):&#xD;
&#xD;
      Participants with DS-TB will be randomized to one of two treatment arms. These participants&#xD;
      will receive either BPaMZ daily for 17 weeks (4 months), or HRZE/HR combination tablets daily&#xD;
      for 26 weeks (6 months). participants will be stratified for co-infection with human&#xD;
      immunodeficiency virus (HIV) and cavitation.&#xD;
&#xD;
      Participants with Drug Resistant TB (DR-TB):&#xD;
&#xD;
      Participants with DR-TB will be assigned to receive BPaMZ daily for 26 weeks (6 months).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 30, 2018</start_date>
  <completion_date type="Anticipated">February 25, 2022</completion_date>
  <primary_completion_date type="Actual">February 22, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Phase 2c multi-center, open-label, partially randomized clinical trial in DS-TB and DR-TB participants</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to culture conversion to negative status over 8 weeks</measure>
    <time_frame>Days 0-56 (8 weeks)</time_frame>
    <description>Culture conversion is a diagnostic criteria indicating the point at which samples taken from a patient infected with a tuberculosis can no longer produce tuberculosis cell cultures, that point is considered culture negativity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants experiencing bacteriologic failure or relapse or clinical failure (unfavourable outcome) at 52 weeks (12 months)</measure>
    <time_frame>At week 52 of treatment</time_frame>
    <description>Culture conversion requires at least 2 consecutive culture negative/positive samples at least 7 days apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of bacteriologic failure or relapse or clinical failure at 104 weeks from the start of therapy.</measure>
    <time_frame>Day 0 - Day 728 (Week 104)</time_frame>
    <description>Culture conversion requires at least 2 consecutive culture negative/positive samples at least 7 days apart.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with sputum culture conversion to negative status in liquid culture (MGIT) at 4, 6, 12 and 17 weeks to be explored as a potential biomarker of outcome at 52 weeks from start of therapy.</measure>
    <time_frame>Week 4, Week 6, Week 12, Week 17, and Week 52</time_frame>
    <description>Culture conversion is a diagnostic criteria indicating the point at which samples taken from a patient infected with a tuberculosis can no longer produce tuberculosis cell cultures, that point is considered culture negativity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weight</measure>
    <time_frame>Day 0 - Day 364 (Week 52)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events (TEAEs) presented by incidence, severity, drug relatedness, seriousness, leading to early withdrawal, and leading to death.</measure>
    <time_frame>Day 0 - Day 364 (Week 52)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">455</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <condition>Tuberculosis, Multidrug-Resistant</condition>
  <condition>Tuberculosis, MDR</condition>
  <condition>Tuberculosis</condition>
  <condition>Drug-Resistant Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Drug Sensitive BPaMZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 9 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 17 weeks (Total treatment duration 4 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Sensitive Standard Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>isoniazid 75 mg + rifampicin 150 mg + pyrazinamide 400 mg + ethambutol 275 mg (HRZE) combination tablets for 8 weeks AND isoniazid 75 mg + rifampicin 150 mg (HR) combination tablets for Weeks 9 to 26</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Resistant BPaMZ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bedaquiline 200 mg daily for 8 weeks then 100 mg daily for 18 weeks, together with pretomanid 200 mg + moxifloxacin 400 mg + pyrazinamide 1500 mg daily for 26 weeks (Total treatment duration 6 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pretomanid</intervention_name>
    <description>200 mg tablets</description>
    <arm_group_label>Drug Resistant BPaMZ</arm_group_label>
    <arm_group_label>Drug Sensitive BPaMZ</arm_group_label>
    <other_name>PA-824</other_name>
    <other_name>Pa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bedaquiline</intervention_name>
    <description>100 mg tablets</description>
    <arm_group_label>Drug Resistant BPaMZ</arm_group_label>
    <arm_group_label>Drug Sensitive BPaMZ</arm_group_label>
    <other_name>B</other_name>
    <other_name>TMC207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxifloxacin</intervention_name>
    <description>400 mg tablets</description>
    <arm_group_label>Drug Resistant BPaMZ</arm_group_label>
    <arm_group_label>Drug Sensitive BPaMZ</arm_group_label>
    <other_name>M</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrazinamide</intervention_name>
    <description>500 mg tablets</description>
    <arm_group_label>Drug Resistant BPaMZ</arm_group_label>
    <arm_group_label>Drug Sensitive BPaMZ</arm_group_label>
    <other_name>Z</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRZE</intervention_name>
    <description>isoniazid 75 mg plus rifampicin 150 mg plus pyrazinamide 400 mg plus ethambutol 275 mg combination tablets</description>
    <arm_group_label>Drug Sensitive Standard Treatment</arm_group_label>
    <other_name>isoniazid</other_name>
    <other_name>rifampicin</other_name>
    <other_name>ethambutol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HR</intervention_name>
    <description>isoniazid 75 mg plus rifampicin 150 mg combination tablets</description>
    <arm_group_label>Drug Sensitive Standard Treatment</arm_group_label>
    <other_name>isoniazid</other_name>
    <other_name>rifampicin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants are required to meet all of the following inclusion criteria during the&#xD;
        screening period in order to be randomized.&#xD;
&#xD;
          1. Signed written consent prior to undertaking any trial-related procedures.&#xD;
&#xD;
          2. Male or female, aged 18 years or over.&#xD;
&#xD;
          3. Body weight (in light clothing and no shoes) ≥ 30 kg.&#xD;
&#xD;
          4. Sputum positive for tubercule bacilli (at least 1+ on the International Union Against&#xD;
             Tuberculosis and Lung Disease [IUATLD]/WHO scale (Appendix 1) on smear microscopy) at&#xD;
             the trial laboratory.&#xD;
&#xD;
          5. Disease Characteristics:&#xD;
&#xD;
               -  Participants with one of the following pulmonary TB conditions:&#xD;
&#xD;
        DS-TB treatment arm participants should be:&#xD;
&#xD;
          1. sensitive to rifampicin and isoniazid by rapid sputum based test AND&#xD;
&#xD;
          2. either newly diagnosed for TB or have a history of being untreated for at least 3&#xD;
             years after cure from a previous episode of TB.&#xD;
&#xD;
        If they are entered into the trial due to being sensitive to rifampicin and isoniazid by&#xD;
        rapid molecular sputum based test, however on receipt of the rifampicin and/or isoniazid&#xD;
        phenotypic resistance testing in liquid culture this shows they are rifampicin or isoniazid&#xD;
        resistant, they will be:&#xD;
&#xD;
          1. Excluded as late exclusions;&#xD;
&#xD;
          2. Possibly replaced as determined by the Sponsor.&#xD;
&#xD;
        DR-TB treatment arm participants should be:&#xD;
&#xD;
        a. Resistant to rifampicin and/or isoniazid. A chest x-ray which in the opinion of the&#xD;
        investigator is compatible with pulmonary TB.&#xD;
&#xD;
        1. Contraception:&#xD;
&#xD;
        Be of non-childbearing potential or using effective methods of birth control, as defined&#xD;
        below:&#xD;
&#xD;
        Non-childbearing potential:&#xD;
&#xD;
          1. Participant - not heterosexually active or practice sexual abstinence; or&#xD;
&#xD;
          2. Female participant or male participants female sexual partner - bilateral&#xD;
             oophorectomy, bilateral tubal ligation and/or hysterectomy or has been postmenopausal&#xD;
             with a history of no menses for at least 12 consecutive months; or&#xD;
&#xD;
          3. Male participant or female participants male sexual partner - vasectomised or has had&#xD;
             a bilateral orchidectomy minimally three months prior to screening;&#xD;
&#xD;
        Effective birth control methods:&#xD;
&#xD;
          1. Double barrier method which can include a male condom, diaphragm, cervical cap, or&#xD;
             female condom; or&#xD;
&#xD;
          2. Female participant: Barrier method combined with hormone-based contraceptives or an&#xD;
             intra-uterine device for the female participant.&#xD;
&#xD;
          3. Male participants' female sexual partner: Double barrier method or hormone-based&#xD;
             contraceptives or an intra-uterine device for the female partner.&#xD;
&#xD;
        And both male and female participants are willing to continue practicing birth control&#xD;
        methods and are not planning to conceive throughout treatment and for 12 weeks after the&#xD;
        last dose of trial medication or discontinuation from trial medication in case of premature&#xD;
        discontinuation.&#xD;
&#xD;
        (Note: Hormone-based contraception alone may not be reliable when taking IMP; therefore,&#xD;
        hormone-based contraceptives alone cannot be used by female participants to prevent&#xD;
        pregnancy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants will be excluded from participation if they meet any of the following&#xD;
        criteria:&#xD;
&#xD;
        Medical History and Concurrent Conditions:&#xD;
&#xD;
          1. Any non-TB related condition where participation in the trial, as judged by the&#xD;
             investigator, could compromise the well-being of the participant or prevent, limit or&#xD;
             confound protocol specified assessments.&#xD;
&#xD;
          2. Being, or about to be, treated for Malaria.&#xD;
&#xD;
          3. Is critically ill and, in the judgment of the investigator, has a diagnosis likely to&#xD;
             result in death during the trial or the follow-up period.&#xD;
&#xD;
          4. TB meningitis or other forms of extrapulmonary tuberculosis with high risk of a poor&#xD;
             outcome, or likely to require a longer course of therapy (such as TB of the bone or&#xD;
             joint), as judged by the investigator.&#xD;
&#xD;
          5. History of allergy or hypersensitivity to any of the trial IMP or related substances,&#xD;
             including known allergy to any fluoroquinolone antibiotic, history of tendinopathy&#xD;
             associated with quinolones or suspected hypersensitivity to any rifampicin&#xD;
             antibiotics.&#xD;
&#xD;
          6. For HIV infected participants any of the following:&#xD;
&#xD;
               1. CD4+ count &lt;100 cells/µL&#xD;
&#xD;
               2. Karnofsky score &lt;60% (Appendix 5)&#xD;
&#xD;
               3. Received intravenous antifungal medication within the last 90 days&#xD;
&#xD;
               4. WHO Clinical Stage 4 HIV disease (Appendix 3)&#xD;
&#xD;
          7. Participants recently started or expected to need to start ART within 1 month after&#xD;
             randomization. Participants may be included who have been on ARTs for greater than 30&#xD;
             days prior to start of screening, or who are expected to start ART greater than 30&#xD;
             days after randomization.&#xD;
&#xD;
          8. Resistant to fluoroquinolones (rapid, sputum-based molecular screening tests).&#xD;
&#xD;
             a. If they are entered into the trial due to being sensitive to fluoroquinolones by&#xD;
             rapid sputum based test, however on receipt of the moxifloxacin phenotypic resistance&#xD;
             testing in liquid culture they are found to be fluoroquinolones resistant, they will&#xD;
             be excluded as late exclusions;&#xD;
&#xD;
          9. Having participated in other clinical trials with investigational agents within 8&#xD;
             weeks prior to start of trial medication or currently enrolled in an investigational&#xD;
             trial;&#xD;
&#xD;
         10. Participants with any of the following at screening (per measurements and reading done&#xD;
             by ECG):&#xD;
&#xD;
         11. Cardiac arrhythmia requiring medication;&#xD;
&#xD;
         12. Prolongation of QT/QTc interval with QTcF (Fridericia correction) &gt;450 ms;&#xD;
&#xD;
         13. History of additional risk factors for Torsade de Pointes, (e.g., heart failure,&#xD;
             hypokalemia, family history of Long QT Syndrome);&#xD;
&#xD;
         14. Any clinically significant ECG abnormality, in the opinion of the investigator.&#xD;
&#xD;
         15. Unstable Diabetes Mellitus which required hospitalization for hyper- or hypo-glycaemia&#xD;
             within the past year prior to start of screening.&#xD;
&#xD;
        Previous and Concomitant Therapy&#xD;
&#xD;
          1. Previous treatment with pretomanid or bedaquiline as part of a clinical trial.&#xD;
&#xD;
          2. Previous treatment for TB which includes, but is not limited to, gatifloxacin,&#xD;
             amikacin, cycloserine, rifabutin, kanamycin, para-aminosalicylic acid, rifapentine,&#xD;
             thioacetazone, capreomycin, quinolones, thioamides, and metronidazole:&#xD;
&#xD;
          3. For DS-TB treatment arms: Previous treatment for tuberculosis within 3 years prior to&#xD;
             Day -9 to -1 (Screening). Participants who have previously received isoniazid&#xD;
             prophylactically may be included in the trial as long as that treatment is/was&#xD;
             discontinued at least 7 days prior to randomization into this trial.&#xD;
&#xD;
          4. For the DR-TB/MDR-TB participants: Previous treatment for DR-TB/MDR-TB, although may&#xD;
             have been on a DR-TB treatment regimen for no longer than 7 days at start of&#xD;
             screening.&#xD;
&#xD;
          5. Any diseases or conditions in which the use of the standard TB drugs or any of their&#xD;
             components is contra-indicated, including but not limited to drug allergy.&#xD;
&#xD;
          6. Use of any drug within 30 days prior to randomisation known to prolong QTc interval&#xD;
             (including, but not limited to, amiodarone, amitriptyline, bepridil, chloroquine,&#xD;
             chlorpromazine, cisapride, clarithromycin, disopyramide dofetilide, domperidone,&#xD;
             droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl,&#xD;
             mesoridazine, methadone, pentamidine, pimozide, procainamide, quinacrine, quinidine,&#xD;
             sotalol, sparfloxacin, thioridazine).&#xD;
&#xD;
          7. Use of systemic glucocorticoids within one year of start of screening (inhaled or&#xD;
             intranasal glucocorticoids are allowed) due to visual opacities or cataracts&#xD;
&#xD;
          8. For HIV infected participants, only the following types of ART are permissible:&#xD;
&#xD;
               -  Nevirapine (NVP) based regimen consisting of NVP in combination with any two&#xD;
                  nucleosidase reverse transcriptase inhibitors (NRTIs) tenofovir (TDF)/abacavir&#xD;
                  (ABC) and emtricitabine (FTC)/lamivudine (3TC).&#xD;
&#xD;
               -  Lopinavir/ritonavir based regimen consisting of lopinavir/ritonavir in&#xD;
                  combination with any two NRTI. TDF/ABC and FTC/3TC.&#xD;
&#xD;
               -  Integrase inhibitor (e.g., dolutegravir) in combination with TDF/ABC and FTC/3TC.&#xD;
&#xD;
               -  In participants who have viral load suppressed on efavirenz at the time of&#xD;
                  screening, their ART can be changed to rilpivirine in combination with TDF/ABC&#xD;
                  and FTC/3TC. If possible, the same nucleoside backbone should be used.&#xD;
&#xD;
          9. In the case where participants are randomized to a rifampicin containing regime&#xD;
&#xD;
               -  EFV can be used with rifampicin.&#xD;
&#xD;
               -  LPV needs to be double dosed.&#xD;
&#xD;
               -  Rilpivirine cannot be given with rifampicin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morounfolu Olugbosi, MD MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Global Alliance for TB Drug Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Evandro Chagas</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FIOCRUZ</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Center for Tuberculosis and Lung Diseases</name>
      <address>
        <city>Tbilisi</city>
        <zip>0101</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Perubatan Respiratori</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lung Center of Philippines</name>
      <address>
        <city>Manila</city>
        <zip>1104</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tropical Disease Foundation</name>
      <address>
        <city>Manila</city>
        <zip>1230</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow City Research and Practice Tuberculosis Treatment Centre</name>
      <address>
        <city>Moscow</city>
        <zip>107014</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central TB Research Institute of the Federal Agency of Scientific Organizations</name>
      <address>
        <city>Moscow</city>
        <zip>107564</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of Phthisiopulmonology of I. M. Sechenov First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of the Phthisiopulmonology</name>
      <address>
        <city>Sankt Petersburg</city>
        <zip>191036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ural Research Institute of Phthisiopulmonology</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>THINK</name>
      <address>
        <city>Pietermaritzburg</city>
        <state>KwaZulu Natal</state>
        <zip>3216</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Madibeng Centre for Research</name>
      <address>
        <city>Brits</city>
        <zip>0250</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TASK</name>
      <address>
        <city>Cape Town</city>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cape Town Lung Institute</name>
      <address>
        <city>Cape Town</city>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enhancing Care Foundation</name>
      <address>
        <city>Durban</city>
        <zip>4001</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU, King Dinuzulu</name>
      <address>
        <city>Durban</city>
        <zip>4015</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU, Helen Joseph Hospital</name>
      <address>
        <city>Johannesburg</city>
        <zip>2092</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PHRU, Tshepong Hospital</name>
      <address>
        <city>Klerksdorp</city>
        <zip>2571</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU, Empilweni TB Hospital</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>7070</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Setshaba Research Centre</name>
      <address>
        <city>Soshanguve</city>
        <zip>0152</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ifakara Health Institute</name>
      <address>
        <city>Bagamoyo</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NIMR-Mbeya</name>
      <address>
        <city>Mbeya</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kilimanjaro Clinical Research Institute</name>
      <address>
        <city>Moshi</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mwanza Intervention Trials Unit</name>
      <address>
        <city>Mwanza</city>
        <country>Tanzania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Kampala</city>
        <zip>2109</zip>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Georgia</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Tanzania</country>
    <country>Uganda</country>
  </location_countries>
  <removed_countries>
    <country>Ethiopia</country>
    <country>Thailand</country>
  </removed_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 3, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tuberculosis</keyword>
  <keyword>drug-resistant tuberculosis</keyword>
  <keyword>TB</keyword>
  <keyword>DR-TB</keyword>
  <keyword>pretomanid</keyword>
  <keyword>PA-824</keyword>
  <keyword>bedaquiline</keyword>
  <keyword>TMC207</keyword>
  <keyword>moxifloxacin</keyword>
  <keyword>pyrazinamide</keyword>
  <keyword>HRZE</keyword>
  <keyword>TB Alliance</keyword>
  <keyword>NC-008</keyword>
  <keyword>drug-sensitive tuberculosis</keyword>
  <keyword>DS-TB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Multidrug-Resistant</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Rifampin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Pyrazinamide</mesh_term>
    <mesh_term>Ethambutol</mesh_term>
    <mesh_term>Bedaquiline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

